

Jianguo Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/102772/publications.pdf>

Version: 2024-02-01

46
papers

1,348
citations

471509

17
h-index

361022

35
g-index

48
all docs

48
docs citations

48
times ranked

2205
citing authors

#	ARTICLE	IF	CITATIONS
1	Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 248-250.	1.5	2
2	Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1077-1087.	2.4	7
3	Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non-Small-Cell Lung Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 786864.	3.5	5
4	Rapid Progress in Intelligent Radiotherapy and Future Implementation. <i>Cancer Investigation</i> , 2022, 40, 425-436.	1.3	6
5	Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20611-e20611.	1.6	3
6	Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database. <i>Journal of Ovarian Research</i> , 2021, 14, 40.	3.0	3
7	Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression. <i>Frontiers in Immunology</i> , 2021, 12, 610149.	4.8	5
8	Attitudes and Practices of Immune Checkpoint Inhibitors in Chinese Patients With Cancer: A National Cross-Sectional Survey. <i>Frontiers in Pharmacology</i> , 2021, 12, 583126.	3.5	2
9	Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 665133.	4.8	41
10	Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database. <i>Frontiers in Oncology</i> , 2021, 11, 630885.	2.8	22
11	The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations. <i>Frontiers in Oncology</i> , 2021, 11, 659065.	2.8	3
12	Factors for incidence risk and prognosis in non-small-cell lung cancer patients with synchronous brain metastasis: a population-based study. <i>Future Oncology</i> , 2021, 17, 2461-2473.	2.4	6
13	Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study. <i>BMC Infectious Diseases</i> , 2021, 21, 760.	2.9	4
14	Clinical characteristics and a decision tree model to predict death outcome in severe COVID-19 patients. <i>BMC Infectious Diseases</i> , 2021, 21, 783.	2.9	14
15	Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination. <i>Future Oncology</i> , 2021, 17, 3477-3484.	2.4	23
16	Optimization of a protocol for contrast-enhanced four-dimensional computed tomography imaging of thoracic tumors using minimal contrast agent. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1021-1031.	2.0	0
17	Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. <i>JAMA Network Open</i> , 2021, 4, e2124750.	5.9	98
18	A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 163, 76-82.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult. <i>Frontiers in Endocrinology</i> , 2021, 12, 805194.	3.5	5
20	Allele Frequency-adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 556-567.	1.1	66
21	Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1. <i>BMC Cancer</i> , 2020, 20, 949.	2.6	22
22	Identification of a prognostic immune-related signature for small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, e21041-e21041.	1.6	0
23	Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, e21526-e21526.	1.6	0
24	Construction of nomograms for nasopharyngeal carcinoma containing primary tumor size and SEER stage. <i>Translational Cancer Research</i> , 2020, 9, 6939-6954.	1.0	6
25	Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. <i>Clinical Cancer Research</i> , 2019, 25, 6967-6975.	7.0	52
26	Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study. <i>Oncology Letters</i> , 2019, 17, 5590-5600.	1.8	22
27	Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations. <i>Oncologist</i> , 2019, 24, 1031-e612.	3.7	48
28	Rab25 promotes erlotinib resistance by activating the β 1 integrin/AKT/ β catenin pathway in NSCLC. <i>Cell Proliferation</i> , 2019, 52, e12592.	5.3	36
29	Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. <i>Thoracic Cancer</i> , 2019, 10, 751-760.	1.9	23
30	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , 2019, 5, 696.	7.1	380
31	Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8873-8877.	2.0	10
32	Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 9035-9035.	1.6	1
33	Clinical benefits of Livin peptide-loaded DCs/CIKs combined with chemotherapy in advanced non-small cell lung cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 406-414.	1.4	6
34	A dosimetric phantom study of thoracic radiotherapy based on three-dimensional modeling of mediastinal lymph nodes. <i>Oncology Letters</i> , 2018, 15, 5634-5642.	1.8	0
35	Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both <i>ATM</i> and <i>HIF-1α</i> . <i>Cancer Medicine</i> , 2018, 7, 3834-3847.	2.8	53
36	Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer. <i>Tumor Biology</i> , 2017, 39, 101042831770963.	1.8	15

#	ARTICLE	IF	CITATIONS
37	Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. <i>Oncotarget</i> , 2017, 8, 17301-17312.	1.8	64
38	A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 543.	2.6	8
39	miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway. <i>International Journal of Oncology</i> , 2016, 48, 1855-1867.	3.3	56
40	Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 11927-11936.	1.8	68
41	IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. <i>Oncology Reports</i> , 2016, 35, 1483-1492.	2.6	11
42	Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. <i>Radiation Oncology</i> , 2016, 11, 60.	2.7	18
43	Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. <i>Oncotarget</i> , 2016, 7, 70535-70545.	1.8	28
44	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. <i>Cancer Letters</i> , 2015, 369, 97-102.	7.2	82
45	Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 159-164.	1.8	9
46	Evaluation of Traffic Injury Prevention Programs Using Counting Process Approaches. <i>Journal of the American Statistical Association</i> , 2001, 96, 469-475.	3.1	9